Latest Strategic Investments News

CTI Logistics has reported a robust half-year performance with revenue climbing 7.6% and profit before tax soaring 64.2%, underpinned by operational efficiencies and strategic investments in Western Australia.

Island Pharmaceuticals reports a 213.8% increase in half-year loss to $4.81 million, driven by strategic acquisition and clinical development investments. The company advances its antiviral portfolio with Galidesivir and ISLA-101, supported by strong US regulatory engagement and a $9 million capital raise.

Vitura Health Limited reported an 8.3% rise in half-year revenues to $67.87 million, driven by medicinal cannabis sales and telehealth services, yet posted a consolidated loss of $986,341 due to margin pressures and increased costs. Leadership changes and strategic investments mark a pivotal phase for the digital health and medicinal cannabis player.

Pharmx Technologies reported a 3.1% revenue increase to $3.89 million for H1 FY26 but posted a net loss of $512,000 driven by strategic investments. The company also announced a significant multi-year alliance with Sigma Healthcare.

Hiremii Limited has reported a record half-year revenue of $16.1 million, boosted by its acquisition of Prince Migration and advances in its AI recruitment platform. Despite a modest loss, the company is positioning itself for growth through technology innovation and strategic capital raises.

Iress Limited reported a 7.4% revenue decline to $556.3 million for FY25 but achieved a 21.5% rise in profit before tax, declaring a fully franked final dividend of 13 cents per share. The company sharpened its focus on core Wealth and Trading software businesses while advancing sustainability and AI innovation.

Imricor Medical Systems saw a sharp 69.5% decline in revenue for 2025, driven by clinical trial impacts, yet narrowed its net loss to $25.3 million as it secured FDA clearance for key products post-year-end.

Acrow Ltd reported a robust 23% revenue increase in 1H FY26, driven by its expanding Industrial Access division, even as net profit fell 22% amid Queensland market softness. The company’s strategic investments and acquisitions position it well for future growth.

Nuchev Limited reported a 12% increase in revenue to $12.38 million for the half-year ended December 2025, driven by growth in core products and offshore markets. However, the company’s net loss widened to $2.34 million amid ongoing investments in marketing, product development, and international expansion.

333D Limited reported a 23% increase in revenue to $588,678 for the half-year ended December 2025, despite a 92% plunge in profit after tax to a $282,030 loss. The company boosted its cash reserves significantly and initiated a strategic Bitcoin investment.

Tetratherix Limited reported a $4.6 million statutory loss for the first half of FY26, driven by increased R&D and manufacturing investments, while making significant progress in clinical trials and securing key global partnerships.

Viva Energy Group Limited reported a significant net loss for 2025, driven by retail asset impairments, yet underlying profits and strategic investments signal resilience and a clear path forward.